Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Ratios

Minerva Neurosciences (NERV) Gains from Sales and Divestitures (2017 - 2020)

Minerva Neurosciences filings provide 2 years of Gains from Sales and Divestitures readings, the most recent being $57075.0 for Q4 2020.

On a quarterly basis, Gains from Sales and Divestitures fell 2.69% to $57075.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $57075.0, a 2.69% decrease, with the full-year FY2020 number at $57075.0, down 2.69% from a year prior.
Gains from Sales and Divestitures hit $57075.0 in Q4 2020 for Minerva Neurosciences, up from $10000.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $58650.0 in Q4 2019 to a low of $10000.0 in Q2 2020.